RxDoctor Payments DataLook up a doctor →

Michael Carducci, MD

Medical Oncology · Baltimore, MDNPI 1952369977

Payments from drug & device makers

$4,795,472in general payments, 2019–2025

Across 338 payments — averaging $14,188 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1.9M
  • Merck$1.4M
  • Pfizer$617K
  • EMD Serono, Inc.$440K
  • Astrazeneca UK Limited$141K
  • Bristol Myers Squibb$73K
  • plus $200K from 8 others
$4,802in research payments, 2019–2025

Across 3 payments — averaging $1600.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$5K

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.27$1,945,215
Merck142$1,379,951
Pfizer40$616,673
EMD Serono, Inc.77$439,558
Astrazeneca UK Limited11$140,820
Bristol Myers Squibb4$73,467
AstraZeneca11$68,652
Gilead5$61,270
Exelixis Inc.9$38,438
Genentech, Inc.3$20,971
Astellas Pharma US Inc6$6,792
Sanofi1$3,605
Eli Lilly1$37
F. Hoffmann-la Roche AG1$22

How this compares

$4,795,472 in reported general payments places this provider in the 90th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$84,491
Medicare patients
247
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →